The LATAM pain management drugs market was valued at $2,683.82 million in 2019, and is projected to reach $3,383.20 million by 2027, registering a CAGR of 3.5% from 2020 to 2027.
Pain is a distressing sensory and emotional sensation, which is caused by tissue injury or disease. Moreover, different disorders may cause discomfort, such as multiple sclerosis, osteoarthritis, stomach ulcer, chronic arthritis, fibromyalgia, diabetic neuropathy, and cancer.
The length of pain ranges from acute pain for short term to chronic pain for long term. Acute pain is a sudden onset of pain while chronic pain is caused by aged bone & joint conditions, nerve damage, or injury. Pain management involves reducing or treating pain by using a given range of medications. There are several medicines available that provide pain relief through a variety of physiological mechanisms such as targeting nociceptors.
Rise in geriatric population is the major factor that drives growth of the LATAM pain management market, as aged people are more prone to suffer from joint pain and other chronic conditions. Moreover, surge in prevalence of chronic diseases, such as cancer, diabetic neuropathy, and osteoarthritis propels market growth in Latin America. Furthermore, rise in number of surgical procedures and rise in healthcare expenditure are expected to fuel growth of the LATAM pain management drugs market. However, drug exploitation, patent expiration of prescription pain medication drugs, and availability of substitutes such as pain relief devices restrain the market growth in Latin America. The LATAM pain management drugs market is segmented on the basis of drug class, indication, and region. On the basis of drug class, the market is categorized into nonsteroidal anti-inflammatory drugs (NSAIDs), anesthetics, anticonvulsants, antimigraine agents, antidepressants, opioids, and nonnarcotic analgesics.
On the basis of indication, the market is divided into arthritic pain, neuropathic pain, cancer pain, chronic back pain, postoperative pain, migraine, fibromyalgia, bone fracture, muscle sprain, acute appendicitis, and others. By region, it is analyzed across Brazil, Argentina, Colombia, Peru, Chile, Ecuador, Panama, and rest of Latin America.
By Drug Class
Opioids is projected as one of the most lucrative segments.
The key players operating in the LATAM pain management drugs market include Novartis AG, Eli Lilly & Company, Abbott Laboratories, Pfizer, Inc., Mylan NV., Merck & Co. Inc., Johnson & Johnson, and GlaxoSmithKline Plc. The other prominent players in the value chain include Allergen Inc., Bayer AG, Bristol-Myers Squibb, Valeant Pharmaceuticals International Inc., Boehringer Ingelheim, WEX Pharmaceuticals, and Zynerba Pharmaceuticals.
Drug class segment review
By drug class, the opioids segment was the largest contributor to the market in 2019, owing to high efficiency of opioids to relieve pain in major chronic conditions. The anesthetics segment is anticipated to possess highest growth rate during the forecast period.
By Indication
Cancer pain is projected as one of the most lucrative segments.
Segment review
By indication, the neuropathic pain segment accounted for a majority of the LATAM pain management drugs market share in 2019, and is expected to exhibit a prominent growth rate during the forecast period. In addition, increase in presence of large patient population is the major factor that increases demand for drugs for this segment. Cancer pain and chronic back pain segments are expected to grow at the highest rate throughout the forecast period, owing to increase in number of surgeries in Latin America and rise in prevalence of chronic diseases that lead to back pain.
Brazil accounted for majority of the LATAM pain management drugs market share in 2019, and is expected to remain dominant throughout the forecast period. This was attributed to large number of aging population and favorable regulatory conditions. Rise in number of drug abuse cases and addictive nature of opioids has decreased use of prescriptions for opioids in the region, leading to decline in opioid consumption for pain management. On the other hand, Argentina is expected to experience highest growth rate during the forecast period, mainly attributable to presence of larger patient pool and increase in healthcare expenditure in the region.
By Country
Argentina is projected as one of the most lucrative markets.
Key Benefits For Stakeholders
- The study provides an in-depth analysis of the LATAM pain management drug market along with the current trends and future estimations to elucidate the imminent investment pockets.
- A comprehensive analysis of the factors that drive and restrict the market growth is provided in the report.
- The LATAM pain management drugs market forecast is studied from 2020 to 2027
- Comprehensive quantitative analysis of the industry from 2019 to 2027 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
- Extensive analysis of the key segments of the industry helps to understand the application and products of pain management used across the globe.
- Key market players and their strategies have been analysed to understand the competitive outlook of the LATAM pain management drugs market.
LATAM Pain Management Drugs Market, by Drug Class, Report Highlights
| Aspects | Details |
 By Drug Class Type |
|
 By Indication |
|
 By Region |
|
 Key Market Players | GRÜNENTHAL, AXON PHARMA, MYLAN N.V., MERCK & CO., INC., JOHNSON & JOHNSON, NOVARTIS INTERNATIONAL AG, ABBOTT LABORATORIES, GLAXOSMITHKLINE PLC (GSK), SANOFI, ELI LILY AND COMPANY, PFIZER INC. |
Analyst Review
The demand for pain management drugs has increased rapidly over recent years. Pain can be caused due to various reasons such as chronic diseases, cancer, and surgeries. Thus, these segments are the largest contributors to the market growth. Presence of large geriatric population base, rise in prevalence of cancer in LATAM countries, and availability of pipeline drugs that pose act as promising treatment options for patients with chronic diseases contribute toward growth of the market.
However, patent expiration of major best-seller drugs such as pregabalin and duloxetine by Pfizer and Eli Lilly & Co., respectively, and availability of alternative therapies such as acupuncture, massage, and medical devices hamper the market growth.
Employment of pain management drugs is on the rise in Latin America, owing to increase in adoption of these drugs, high prevalence of chronic diseases, and increase in disposable income of customers. In addition, presence of a large geriatric population in Latin American countries and favorable regulatory & healthcare reforms towards pain management drugs are expected to drive the market. The adoption rate is expected to increase, owing to rise in disposable income and surge in incidences of chronic diseases. Moreover, increase in R&D investments, surge in healthcare expenditure, and rise in government funding & initiatives propel the market growth in LATAM.
The total value of LATAM Pain Management Drugs market was $2,683.2 million in 2019.
The forecast period in the report is from 2020-2027.
The market value of Pain Management Drugs market in 2020 was $2,652.28 million.
The base year calculated is 2019 in the report.
The demand for pain management drugs has increased rapidly over recent years. Pain can be caused due to various reasons such as chronic diseases, cancer, and surgeries. Thus, these segments are the largest contributors to the market growth. Presence of large geriatric population base, rise in global prevalence of cancer, and availability of pipeline drugs that pose to be promising treatment options for patients with chronic diseases contribute to growth of the market.
Rise in geriatric population is the major factor that drives growth of the global pain management market as aged people are more prone to suffer from joint pain and other chronic conditions. Moreover, surge in prevalence of chronic diseases, such as cancer, diabetic neuropathy, and osteoarthritis propels the market growth. Furthermore, rise in number of surgical procedures and rise in healthcare expenditure are expected to fuel growth of the market. However, drug exploitation, patent expiration of prescription pain medication drugs, and availability of substitutes such as pain relief devices restrain the market growth.
The growth % of the LATAM Pain Management Drugs market is 3.5%.
Opioids segment holds the maximum market share.
Loading Table Of Content...
